Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 3/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 2/20 | 0.33 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.33 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6228904 | 0.89 | TAAR1 (0.45) | TAAR1HTR2CDDB1CRBNHTR2A | |
| SCHEMBL9030265 | 0.76 | KDM1A (0.46) | ALDH1A1KDM1ALMNA | |
| SCHEMBL6653603 | 0.75 | GAA (0.45) | HTR2CHTR2BALDH1A1 | |
| SCHEMBL4169809 | 0.74 | TAAR1 (0.45) | TAAR1HTR2CDDB1CRBNHTR2A | |
| SCHEMBL3389545 | 0.73 | NOS1 (0.46) | TAAR1HTR2CALDH1A1MAOBMAOA | |
| SCHEMBL1828071 | 0.73 | TAAR1 (0.44) | TAAR1HTR2CDDB1CRBNHTR2A | |
| SCHEMBL4998332 | 0.69 | HTR2C (0.50) | HTR2CHTR2AHTR2BALDH1A1LMNA | |
| SCHEMBL103011 | 0.68 | ALDH1A1 (0.40) | DDB1CRBNALDH1A1LMNA | |
| SCHEMBL6658015 | 0.67 | TAAR1 (0.45) | TAAR1HTR2CHTR2AHTR2BALDH1A1 | |
| SCHEMBL1515219 | 0.66 | HTR2C (0.67) | HTR2CDDB1CRBNHTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115192711-A | Use of PDE7 inhibitors for the treatment of movement disorders | 奥默罗斯公司 | 2022-10-18 | — | — | CN | disclosed |
| EP-4070801-A1 | COMPOSITIONS OF INSULIN AND CHROMIUM FOR THE TREATMENT AND PREVENTION OF DIABETES, HYPOGLYCEMIA AND RELATED DISORDERS | Nutrition 21, LLC (US) | 2022-10-12 | — | — | EP | disclosed |
| EP-2680861-B1 | COMPOSITIONS OF INSULIN AND CHROMIUM FOR THE TREATMENT AND PREVENTION OF DIABETES, HYPOGLYCEMIA AND RELATED DISORDERS | NUTRITION 21 LLC (US) | 2022-05-04 | — | — | EP | disclosed |
| WO-2021084166-A1 | GOLD NANOSTRUCTURE COMPRISING ENZYMES AND ANTIOXIDANTS | BIO EVEN SAS (FR) | 2021-05-06 | — | — | WO | disclosed |
| CN-104758291-B | Use of PDE7 inhibitors for the treatment of movement disorders | 奥默罗斯公司 | 2020-03-03 | — | — | CN | disclosed |
| EP-2292733-B1 | Production from blood of cells of neural lineage | KWALATA TRADING LTD (CY) | 2019-09-25 | — | — | EP | disclosed |
| US-20190183824-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | OMEROS CORPORATION | 2019-06-20 | — | — | US | disclosed |
| EP-2427193-B1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | OMEROS CORP (US) | 2018-07-11 | — | — | EP | disclosed |
| US-20160015715-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | OMEROS CORPORATION | 2016-01-21 | — | — | US | disclosed |
| US-9119822-B2 | Use of PDE7 inhibitors for the treatment of movement disorders | OMEROS CORPORATION (US) | 2015-09-01 | — | — | US | disclosed |
| EP-0770389-B1 | Use of monosialoganglioside GM1 or N-dichloro-acetyl-lyso-GM1 for preventing or reversing neuronal degeneration induced by a long term treatment with L-DOPA in the therapy of Parkinson's disease | FIDIA FARMACEUTICI (IT) | 2001-09-26 | — | — | EP | disclosed |
| EP-0770389-A1 | Use of monosialoganglioside GM1 or N-dichloro-acetyl-lyso-GM1 for preventing or reversing neuronal degeneration induced by a long term treatment with L-DOPA in the therapy of Parkinson's disease | FIDIA S.p.A. (IT) | 1997-05-02 | — | — | EP | disclosed |
| EP-0630250-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING MONOSIALOGANGLIOSIDE GM 1? OR A DERIVATIVE THEREOF SUITABLE FOR THE TREATMENT OF PARKINSON'S DISEASE | FIDIA S.p.A. (IT) | 1994-12-28 | — | — | EP | disclosed |
| WO-1993017691-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING MONOSIALOGANGLIOSIDE GM1 OR A DERIVATIVE THEREOF SUITABLE FOR THE TREATMENT OF PARKINSON'S DISEASE | FIDIA S.P.A. (IT) | 1993-09-16 | — | — | WO | disclosed |
| US-5206226-A | Method of treatment of Parkinsons's disease using phytic acid | SABIN ROBERT (US) | 1993-04-27 | — | — | US | disclosed |
| US-5187162-A | Methods of treating neurodegenerative conditions | GENSIA PHARMACEUTICALS (US) | 1993-02-16 | — | — | US | disclosed |
| EP-0491792-A4 | METHODS OF TREATING NEURODEGENERATIVE CONDITIONS | — | 1992-12-02 | — | — | EP | disclosed |
| EP-0491792-A1 | METHODS OF TREATING NEURODEGENERATIVE CONDITIONS | GENSIA, INC. (US) | 1992-07-01 | — | — | EP | disclosed |
| US-5112814-A | Method of treatment of Parkinson's disease using phytic acid | SABIN ROBERT (US) | 1992-05-12 | — | — | US | disclosed |
| WO-1991004032-A1 | METHODS OF TREATING NEURODEGENERATIVE CONDITIONS | GENSIA PHARMACEUTICALS, INC. (US) | 1991-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160015715-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | PARK7, PDE7B, PDE7A | TAAR1 1344/4885HTR2C 972/4885DDB1 3464/4885 |
| US-20190183824-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | PARK7, PDE7B, PDE7A | TAAR1 1344/4885HTR2C 972/4885DDB1 3464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.